[an error occurred while processing this directive] | [an error occurred while processing this directive]
Research progress on postoperative application of vaginal brachytherapy in patients with early endometrial carcinoma
Qin Xue, Yan Junfang, Yang Bo, Hou Xiaorong, Yu Lang, Qiu Jie
Departments of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
Abstract Radiation therapy plays an important role in the adjuvant treatment of patients with early endometrial carcinoma. Vaginal stump is a common site of disease failure for early endometrial carcinoma patients with intermediate-high risk factors for recurrence. Compared with external beam radiotherapy, vaginal brachytherapy (VBT) can achieve comparable local control rate with fewer toxicities. In this article, research progresses upon the application of VBT in patients with early endometrial carcinoma after hysterectomy were investigated from multiple perspectives of the selection of patients, the selection of vaginal applicator, factors influencing dose distribution, image-guided adaptive brachytherapy, the design and implementation of radiotherapy regime. In addition, the application of intensity-modulated VBT and the usage of novel quality assurance equipment were also discussed.
Fund:National Key Research and Development Plan, Ministry of Science and Technology of the People′s Republic of China (2016YFC0105206);Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences (2019XK320046);Young Scientific Research Programof Peking Union Medical College. (pumch201910569)
Qin Xue,Yan Junfang,Yang Bo et al. Research progress on postoperative application of vaginal brachytherapy in patients with early endometrial carcinoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(10): 1089-1093.
Qin Xue,Yan Junfang,Yang Bo et al. Research progress on postoperative application of vaginal brachytherapy in patients with early endometrial carcinoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(10): 1089-1093.
[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI:10.3322/caac.21338. [2] Bendifallah S, Canlorbe G, Raimond E, et al. A clue towards improving the European society of medical oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion[J]. Br J Cancer, 2014, 110(11):2640-2646. DOI:10.1038/bjc.2014.237. [3] 谢玲玲,林荣春,林仲秋. 国际权威子宫内膜癌诊治指南解读[J]. 实用妇产科杂志, 2020, 36(6):428-432. DOI:1003-6946(2020)06-0428-05. Xie LL, Lin RC, Lin ZQ. Interpretation of international authoritative guidelines for diagnosis and treatment of endometrial cancer[J]. J Pract ObstetrGynecol, 2020, 36(6):428-432. DOI:1003-6946(2020)06-0428-05. [4] Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer:diagnosis, treatment and follow-up[J]. Ann Oncol, 2016, 27(1):16-41. DOI:10.1093/annonc/mdv484. [5] Wortman BG, Bosse T, Nout RA, et al. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer:evaluation of the pilot phase of the PORTEC-4a trial[J].Gynecol Oncol, 2018, 151(1):69-75. DOI:10.1016/j.ygyno.2018.07.020. [6] Creutzberg CL, Van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma:multicentre randomised trial. PORTEC study group. Post operative radiation therapy in endometrial carcinoma[J]. Lancet, 2000, 355(9213):1404-1411. DOI:10.1016/s0140-6736(00)02139-5. [7] Keys HM, Roberts JA, Brunetto VL, et al. A phase Ⅲ trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma:a gynecologic oncology group study[J].Gynecol Oncol, 2004, 92(3):744-751. DOI:10.1016/j.ygyno.2003.11.048. [8] Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2):an open-label, non-inferiority, randomised trial[J]. Lancet, 2010, 375(9717):816-823. DOI:10.1016/S0140-6736(09)62163-2. [9] Hass P, Seinsch S, Eggemann H, et al. Vaginal brachytherapy for endometrial cancer[J]. J Cancer Res Clin Oncol, 2018, 144(8):1523-1530. DOI:10.1007/s00432-018-2659-8. [10] Randall ME, Filiaci V, McMeekin DS, et al. Phase Ⅲ trial:adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer[J]. J Clin Oncol, 2019, 37(21):1810-1818. DOI:10.1200/JCO.18.01575. [11] Harkenrider MM, Grover S, Erickson BA, et al. Vaginal brachytherapy for postoperative endometrial cancer:2014 survey of the American brachytherapy society[J]. Brachytherapy, 2016, 15(1):23-29. DOI:10.1016/j.brachy.2015.09.012. [12] Govindaraj K, Shanmugam S, Sampathrajan S. Design and development of in-house multichannel applicator for HDR vaginal brachytherapy and dosimetric comparision with single channel applicator[J]. Asian Pac J Cancer Prev, 2019, 20(12):3805-3810. DOI:10.31557/APJCP.2019.20.12.3805. [13] Demanes DJ, Rege S, Rodriquez RR, et al. The use and advantages of a multichannel vaginal cylinder in high-dose-rate brachytherapy[J]. Int J Radiat Oncol Biol Phys, 1999, 44(1):211-219. DOI:10.1016/s0360-3016(98)00453-2. [14] Hou X, Liu A, Zhang F, et al. Dosimetric advantages of using multichannel balloons compared to single-channel cylinders for high-dose-rate vaginal cuff brachytherapy[J]. Brachytherapy, 2016, 15(4):471-476. DOI:10.1016/j.brachy.2016.03.002. [15] Vanneste BG, Meijnen P, Hammerstein CS, et al. Postoperative brachytherapy for endometrial cancer using a ring applicator[J]. Brachytherapy, 2015, 14(2):273-278. DOI:10.1016/j.brachy.2014.10.002. [16] Tuncel N, Garipagaoglu M, Kizildag AU, et al. Optimisation techniques in vaginal cuff brachytherapy[J]. Br J Radiol, 2009, 82(983):936-940. DOI:10.1259/bjr/50204374. [17] Humphrey P, Cornes P, Al-Booz H. Vaginal vault brachytherapy in endometrial cancer:verifying target coverage with image-guided applicator placement[J]. Br J Radiol, 2013, 86(1023):20120428. DOI:10.1259/bjr.20120428. [18] Richardson S, Palaniswaamy G, Grigsby PW. Dosimetric effects of air pockets around high-dose rate brachytherapy vaginal cylinders[J]. Int J Radiat Oncol Biol Phys, 2010, 78(1):276-279. DOI:10.1016/j.ijrobp.2009.11.004. [19] Sikorska K, Zolciak-Siwinska A, Kowalczyk A, et al. Dosimetric evaluation of vaginal cuff brachytherapy planning in cervical and endometrial cancer patients[J]. J Contemp Brachytherapy, 2020, 12(3):248-251. DOI:10.5114/jcb.2020.96865. [20] Magné N, Chargari C, SanFilippo N, et al. Technical aspects and perspectives of the vaginal mold applicator for brachytherapy of gynecologic malignancies[J]. Brachytherapy, 2010, 9(3):274-277. DOI:10.1016/j.brachy.2009.08.014. [21] 晏俊芳. 3D打印技术在妇科恶性肿瘤术后阴道腔内照射中的应用研究[D]. 北京:北京协和医学院, 2018. Yan JF. The application of 3D printing technique in postoperative intravaginal brachytherapy[D]. Beijing:Peking Union Medical College, 2018. [22] Logar H, Hudej R,Segedin B. Development and assessment of 3D-printed individual applicators in gynecological MRI-guided brachytherapy[J]. J Contemp Brachytherapy, 2019, 11(2):128-136. DOI:10.5114/jcb.2019.84741. [23] Biltekin F, Akyol HF, Gültekin M, et al. 3D printer-based novel intensity-modulated vaginal brachytherapy applicator:feasibility study[J]. J Contemp Brachytherapy, 2020, 12(1):17-26. DOI:10.5114/jcb.2020.92407. [24] Sabater S, Arenas M, Berenguer R, et al. Dosimetric analysis of rectal filling on rectal doses during vaginal cuff brachytherapy[J]. Brachytherapy, 2015, 14(4):458-463. DOI:10.1016/j.brachy.2015.02.391. [25] Sabater S, Andrés I, Gascon M, et al. Effect of rectal enemas on rectal dosimetric parameters during high-dose-rate vaginal cuff brachytherapy:a prospective trial[J]. Strahlenther Onkol, 2016, 192(4):248-253. DOI:10.1007/s00066-016-0940-9. [26] Hung J, Shen S, De Los Santos JF, et al. Image-based 3D treatment planning for vaginal cylinder brachytherapy:dosimetric effects of bladder filling on organs at risk[J]. Int J Radiat Oncol Biol Phys, 2012, 83(3):980-985. DOI:10.1016/j.ijrobp.2011.08.023. [27] Iatì G, Pontoriero A, Mondello S, et al. Three-dimensional treatment planning for vaginal cuff brachytherapy:dosimetric effects on organs at risk according to patients position[J]. Brachytherapy, 2014, 13(6):568-571. DOI:10.1016/j.brachy.2014.06.001. [28] Hoskin PJ, Bownes P, Summers A. The influence of applicator angle on dosimetry in vaginal vault brachytherapy[J]. Br J Radiol, 2002, 75(891):234-237. DOI:10.1259/bjr.75.891.750234. [29] Patel S, Mehta KJ, Kuo HC, et al. Do changes in interfraction organ at risk volume and cylinder insertion geometry impact delivered dose in high-dose-rate vaginal cuff brachytherapy?[J]. Brachytherapy, 2016, 15(2):185-190. DOI:10.1016/j.brachy.2015.11.004. [30] Onderdonk BE, Wu T, Al-Hallaq H, et al. Clinical and dosimetric implications of intrafractional cylinder movement during vaginal cuff brachytherapy[J]. Cureus, 2019, 11(11):e6165. DOI:10.7759/cureus.6165. [31] Rivard MJ, Coursey BM, DeWerd LA, et al. Update of AAPM Task Group No. 43 Report:a revised AAPM protocol for brachytherapy dose calculations[J]. Med Phys, 2004, 31(3):633-674. DOI:10.1118/1.1646040. [32] Kim H, Kim H, Houser C, et al. Is there any advantage to three-dimensional planning for vaginal cuff brachytherapy?[J]. Brachytherapy, 2012, 11(5):398-401. DOI:10.1016/j.brachy.2011.12.009. [33] 张宁,韩东梅,程光惠. 超声引导施源器植入在宫颈癌BT的应用[J]. 中华放射肿瘤学杂志,2018, 27(6):616-620. DOI:10.3760/cma.j.issn.1004-4221.2018.06.017. Zhang N, Han DM, Cheng GH. Application of ultrasound-guided applicator placement in brachytherapy for cervical cancer[J]. Chin J Radiat Oncol, 2018, 27(6):616-620. DOI:10.3760/cma.j.issn.1004-4221.2018.06.017. [34] Chapman CH, Prisciandaro JI, Maturen KE, et al. MRI-based evaluation of the vaginal cuff in brachytherapy planning:are we missing the target?[J]. Int J Radiat Oncol Biol Phys, 2016, 95(2):743-750. DOI:10.1016/j.ijrobp.2016.01.042. [35] Zhou J, Prisciandaro J, Lee C, et al. Single or multi-channel vaginal cuff high-dose-rate brachytherapy:Is replanning necessary prior to each fraction?[J]. Pract Radiat Oncol, 2014, 4(1):20-26. DOI:10.1016/j.prro.2012.12.005. [36] Symon Z, Menhel J, Alezra D, et al. Individual fraction optimization vs. first fraction optimization for multichannel applicator vaginal cuff high-dose-rate brachytherapy[J]. Brachytherapy, 2006, 5(4):211-215. DOI:10.1016/j.brachy.2006.07.002. [37] Ebert MA. Possibilities for intensity-modulated brachytherapy:technical limitations on the use of non-isotropic sources[J]. Phys Med Biol, 2002, 47(14):2495-2509. DOI:10.1088/0031-9155/47/14/309. [38] Callaghan CM, Adams Q, Flynn RT, et al. Systematic review of intensity-modulated brachytherapy (IMBT):static and dynamic techniques[J]. Int J Radiat Oncol Biol Phys, 2019, 105(1):206-221. DOI:10.1016/j.ijrobp.2019.04.009. [39] Liu Y, Flynn RT, Kim Y, et al. Dynamic rotating-shield brachytherapy[J]. Med Phys, 2013, 40(12):121703. DOI:10.1118/1.4828778. [40] Liu Y, Flynn RT, Kim Y, et al. Paddle-based rotating-shield brachytherapy[J]. Med Phys, 2015, 42(10):5992-6003. DOI:10.1118/1.4930807. [41] Safigholi H, Meigooni AS, Song WY. Comparison of (192) Ir,(169) Yb, and (60) Co high-dose rate brachytherapy sources for skin cancer treatment[J]. Med Phys, 2017, 44(9):4426-4436. DOI:10.1002/mp.12335. [42] Romanyukha A, Carrara M, Mazzeo D, et al. An innovative gynecological HDR brachytherapy applicator system for treatment delivery and real-time verification[J]. Phys Med, 2019, 59:151-157. DOI:10.1016/j.ejmp.2019.03.001.
2021, Vol. 30 
